Quantcast
Home > Quotes > BOLD

Audentes Therapeutics, Inc. Common Stock (BOLD) Quote & Summary Data

BOLD 
$23.985
*  
0.505
2.15%
Get BOLD Alerts
*Delayed - data as of Dec. 12, 2018 9:33 ET  -  Find a broker to begin trading BOLD now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    BOLD Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 23.31 / $ 24.21
Today's High / Low
$ 23.985 / $ 23.82
Share Volume
2,384
50 Day Avg. Daily Volume
660,573
Previous Close
$ 23.48
52 Week High / Low
$ 46.1799 / $ 19.622
Market Cap
1,023,917,108
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
2,384
50 Day Avg. Daily Volume:
660,573

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.38

Trading Range

The current last sale of $23.985 is 22.24% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 23.985 $ 46.1799
 Low: $ 23.82 $ 19.622

Company Description (as filed with the SEC)

We are a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. We believe that gene therapy has powerful potential to treat these diseases through delivery of a functional copy of the gene to affected cells, resulting in production of the normal protein. We have built a compelling portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy, or XLMTM, AT342 for the treatment of Crigler-Najjar Syndrome, or Crigler-Najjar, AT982 for the treatment of Pompe disease and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia, or CASQ2-CPVT. We have initiated Phase 1/2 clinical studies in our AT132 and AT342 programs, and plan to provide interim data from these studies in the second quarter of 2018.  ... More ...  


Risk Grade

Where does BOLD fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 23.82
Open Date:
Dec. 12, 2018
Close Price:
$ 23.48
Close Date:
Dec. 11, 2018

Consensus Recommendation

Analyst Info